VetSurgeon members Ian and Gillian Mostyn, and the team at Pennine Vets are doing the Coniston Challenge later this year: 30kms of arduous cycling, hiking and canoeing for Guide Dogs.
You can support them with a donation, however small (£2 minimum) at: http://www.justgiving.com/penninevetschallenge.
Virbac, in conjunction with the European Veterinary Dental Society, has launched an online dental charting system called the Electronic Veterinary Dental Scoring System for use by small animal practitioners.
The system aims to enhance the performance of clinicians conducting dentistry and to encourage a thorough review of the oral cavity during the annual check up.
The system allows you to record clinical findings on online dental charts and build up a history for each patient. There are also a series of tutorials to help in making clinical decisions. Virbac says the e-VDS system also encourages owner compliance with treatment regimes as it provides downloadable materials, including an assessment of their pet and follow up reports.
Dr Gottfried Morgenegg-Wegmüller, who was the EVDS project lead on this development, said: "It was always my vision to give veterinary dentistry the importance it deserves. The most effective way to achieve this is by targeting the general practitioner and encouraging them to have a closer look at the oral cavity of their patients."
Victoria Hudson, Product Manager for dental products at Virbac, said: "Poor dental health is a major issue for dogs and cats yet many practices are yet to capitalise on the opportunity to help increase the animal's welfare and health. Many owners are simply unaware of the importance of caring for their pet's teeth.
"The new e-VDS system is a great leap forward in dental care, offering not just electronic charting but a raft of additional support materials, all of which are practical and easy to use. We hope many practices will be keen to try it - and will soon be reaping the benefit!"
e-VDS is available free of charge on http://www.my-virbac.co.uk/, Virbac's practice support portal. Practices can also contact their territory manager for more details.
In an AI position statement released on their website, the company highlights the opportunities and risks associated with the use of AI to interpret diagnostic images.
In the joint statement, company owners Victoria Johnson and Julien Labruyère (pictured right), said: “We strongly welcome the introduction of appropriately developed, tested and implemented AI tools into our profession, to provide solutions to improve resourcing and benefit animal welfare.
“There is a limited pool of veterinary radiologists and an ever-increasing need for expert interpretation of radiographs and more advanced diagnostic imaging modalities.
"This presents a huge opportunity for the development of AI and related technologies to better address demand, save time and potentially improve clinical knowledge and outcomes.
"However, it is important to note that, unlike human radiology, there is no official framework for the regulation, governance and quality control of AI tools in veterinary radiology.
"This means that there should be a very strong onus on companies and individuals to adhere to the highest standards of medical tool development when creating AI solutions.”
“If AI is released into veterinary practice without appropriate oversight or governance there is a significant risk of misleading results, misdiagnosis, and negative impacts on patient welfare.
"This, in turn, may undermine trust in AI and create a culture of hesitancy to adopt new technologies at a time when innovation is much needed to improve access to advanced care.”
The company is advocating for a series of self-regulatory measures to be applied by companies developing AI in order to safeguard both animal welfare and the liability of the veterinary surgeons using these tools in clinical practice.
The full position statement and a list of recommendations can be here: https://www.vet-ct.com/gb/our-services/ai-veterinary-radiology/
Gil Riley of the Pool House Veterinary Hospital in Lichfield, Staffordshire has won the annual Petplan Equine Vet of the Year Award.
The Award was announced at the 21st annual Animal Health Trust (AHT) Equestrian Awards gala dinner held at the Lancaster Hotel in London last Thursday.
Horse owners from all over the UK nominated vets who had gone above and beyond the call of duty. A short list of three finalists was then drawn up and the winner selected by an independent panel consisting of: Peter Webbon AHT Chief Executive and Equine Vet, Alison Bridge Editor-in-Chief of Horse & Rider Magazine, Chris House President of the British Equine Veterinary Association (BEVA) and Jo Whitaker Marketing Development Manager for Petplan.
Peter Webbon of the AHT said "We received a record number of nominations this year and the standards were incredibly high. However, Gil was nominated by over 100 clients and we felt he was truly deserving of this award."
Alison Andrew, Marketing Manager for Petplan said: "This award recognises the amazing hard work and commitment of people within the equine veterinary profession and those who provide outstanding service to horse owners."
Gil joined the Pool House Veterinary Group and Equine clinic practice to expand his equine skills after working in a mainly agricultural practice in Wales and is jointly responsible for the Equine part of the Practice. He has subsequently been awarded the Royal College of Veterinary Surgeons Certificate in Equine Practice and he is particularly interested in lameness and laminitis. He also recently acted as British Team Vet at the International Driving Trials in Germany.
Gil said: "Everyday I feel like I'm pulling the greatest trick in that I get paid for doing what I love. To receive further recognition with this award almost feels greedy. I'm tremendously flattered and indebted to all my clients who nominated me."
In his acceptance speech Gil praised his team for their dedication and support without whom, he said this would not have been possible. Special thanks went to his proud wife Emma on the evening of their fifth wedding anniversary.
The Animal Health Trust Equestrian awards are designed to recognise the outstanding achievements made by horses, riders, owners and trainers throughout the equestrian world. Since the Petplan Charitable Trust was founded in 1994 it has raised over £5million, almost £500,000 of which has been donated to the AHT to fund research and development.
Mary Bale, 45, has been banned from keeping animals for five years today after she admitted causing unnecessary suffering to a cat which she dumped in a wheelie bin, in a case brought by the RSPCA.
Bale, of St Michael's Road, Coventry, was also fined £265 and ordered to pay the costs of the case, which totalled £1,171.
Coventry magistrates' court heard how Bale picked up the four-year-old tabby cat, named Lola, outside the cat's home in Brays Lane, Coventry, and put her into the bin on Saturday 21 August this year.
Lola's owners, Stephanie and Darryl Andrews-Mann, discovered their cat inside the wheelie bin the next day. She had been there for approximately 15 hours.
Upon viewing their CCTV the owners saw Bale approach Lola, who was sitting on a garden wall. She then looked both ways before picking the cat up by the scruff of her neck and dropping her into the bin.
The RSPCA was alerted after the footage was posted on the internet and Bale was identified.
District Judge Caroline Goulborn said: "I accept that you were in a stressful situation but that is no excuse. The potential to cause harm to the cat was substantial."
RSPCA inspector Nicola Foster said: "This was a deliberate act and could have had far worse consequences as the defendant had no way of knowing if there was anything like broken glass in the bin, nor how long the cat would be there before she was found, nor if the bin was due to be emptied.
"We are pleased that the Court agreed that a complete disregard was shown for the cat's welfare and that the cat suffered/cat's needs were not met as a result of being stuck inside the bin for so many hours.
"However, we hope that this sentence will act as a deterrent to anyone who feels that it is acceptable to mistreat animals in any way."
In mitigation, Bale said that her father had been taken to hospital following a fall. She said she walked past the house daily and regularly stroked Lola. She said she had asked herself on an hourly basis since the incident why she had put Lola in the bin, but had no answer.
The new machine is a modular system using low-flow anaesthesia for animals from 2-80kg.
The company says that compared to anaesthetic techniques which use high fresh gas flow rates, it functions without posing a risk to team members from the huge amounts of oxygen and inhalational anaesthetic agents that would otherwise be released.
In turn, this results in cost savings from unwasted agents, and a typical 5 to 10 times reduction in environmental damage.
Darvall founder, Dr Colin Dunlop, said: “For optimal outcome from anaesthesia, veterinary anaesthesiologists and veterinarians routinely make decisions about the physiological well-being of the patient, the environmental impact of their actions, the operational efficiency of their practice and cost-effectiveness.
"Having suitable equipment that uses low-flow anaesthesia will reduce the risk of hypothermia, improve team safety, reduce environmental emissions and reduce costs.”
“Low-flow anaesthesia not only reduces oxygen flows and inhalant agent consumption to less than 10% of high-flow, non-rebreathing systems, it can help reduce anaesthetic hypothermia because it uses warm gas when using the Darvall heated breathing circuits.
"Using our specifically designed modern system for veterinary patients addresses the traditional challenges associated with low-flow anaesthesia and hypothermia.
Darvall says the use of just one system will also simplify staff training and ensure familiarity.
https://darvallvet.com
The RCVS Disciplinary Committee has directed that a veterinary surgeon from Berkshire be removed from the Register, following his administration of a prohibited substance to a racehorse and his subsequent attempts to conceal his actions.
At a six-day hearing that concluded yesterday, James Main, a partner in the O'Gorman, Slater, Main & Partners veterinary practice in Newbury, and former lead veterinary surgeon to racehorse trainer Nicky Henderson, faced four charges of serious professional misconduct concerning his treatment of Moonlit Path, a six-year-old mare owned by The Queen.
Three of the charges related to Mr Main breaching British Horseracing Authority (BHA) rules by injecting Moonlit Path with tranexamic acid (TA) on the day she was due to race; the fourth charge related to his dishonest concealment of this treatment in his practice clinical records. Nicky Henderson had himself faced a BHA Inquiry into this case in 2009 and subsequently been sanctioned.
The Committee heard that on 18 February 2009, Mr Henderson's yard requested a veterinary surgeon attend Moonlit Path to administer an injection of Dycenene the following morning. The injection was requested as the mare was prone to exercise-induced pulmonary haemorrhage. Mr Main attended on the morning of 19 February and injected the horse with intravenous tranexamic acid. Moonlit Path raced at Huntingdon later that day, along with the eventual winner, and favourite, Ravello Bay - another horse trained by Mr Henderson. Moonlit Path finished sixth and a urine sample taken from her after the race tested positive for TA.
Of the four charges, Mr Main admitted injecting Moonlit Path with TA on the day she was due to race when he knew this breached the BHA's rule prohibiting any substance other than the horse's usual feed and water being given on race day. However, Mr Main denied knowing that, if tested, a horse would test positive for TA (thereby imposing a strict liability on the trainer); he denied administering a prohibited substance to a horse with the intention to affect that horse's racing performance; and, he denied dishonestly concealing the TA injection by omitting it from his clinical records and referring to it as a 'pre-race check'.
The Committee heard and carefully considered evidence from Mr Henderson and his employees, from BHA investigating officers and its Director of Equine Science and Welfare, from an expert equine physiologist and from Mr Main himself. In its findings, the Committee stated it was "unimpressed by Mr Henderson's evidence and surprised by his apparent lack of knowledge of the rules of racing".
Whilst the Committee accepted Mr Main believed at the time that Moonlit Path would not test positive for TA, it considered he failed to fully inform himself of the medicinal product he was using; especially so as TA does not possess a Marketing Authorisation as a veterinary medicinal product. In so doing, he did not meet his professional obligation to provide Mr Henderson with the information and advice he needed.
The Committee concluded that TA was a prohibited substance and, whilst accepting that Mr Main's concern had solely been for Moonlit Path's welfare, he had actually breached BHA rules by affecting her performance through administering such a substance.
Finally, the Committee found that Mr Main had deliberately concealed the TA injection to Moonlit Path by describing it in his notes as a 'pre-race check' - a protocol developed over several years between the practice and Mr Henderson. Such inaccurate clinical records were in breach of the RCVS Guide to Professional Conduct and led the Committee to conclude he had acted dishonestly. The Committee also found Mr Main "did not act with candour" by claiming to have administered the TA injection the day before the race. On questioning by the Legal Assessor, however, he admitted that he had known that Moonlit Path was racing the same day that he administered the injection.
Professor Sheila Crispin, chairing the Committee, said: "[We] regard it as wholly unacceptable practice that a veterinary surgeon should be party to serious breaches of rules of another regulatory body in the field of animal welfare ... and which go to the very integrity of racing.
"Whilst the findings relate to a single incident, [we] are satisfied that Mr Main's actions amounted to pre-meditated misconduct ... It is highly relevant that Mr Main held positions of responsibility within the racing industry where he was required to uphold the rules and standards of the profession," she added.
Noting Mr Main's "long and hitherto unblemished career as a highly respected equine veterinary surgeon", the Committee accepted Mr Main's evidence that the reason for the administration of tranexamic acid was solely his concern about the welfare of the horse. Nevertheless, it found his evidence was "evasive, lacking in candour and on some aspects of the case his evidence was untrue".
Professor Crispin concluded: "...proven dishonesty has been held to come at the top end of the spectrum of gravity of disgraceful conduct in a professional respect ... Having considered carefully all the mitigation put forward on Mr Main's behalf, [we] have concluded that Mr Main's behaviour was wholly unacceptable and so serious that removal of his name from the Register is required."
Virbac, maker of Pronefra for the management of CKD in cats and dogs, has launched a free app to help interpret patients' urine test results in line with the latest International Renal Interest Society (IRIS) Guidelines.
The app, which is also called Pronefra, is available for download on both the Play store and Apple store.
Simon Boulton MRCVS, Marketing Manager for Companion Animals, said: "Reference ranges supplied by machines and labs are not always appropriate for the renal patient so we wanted to help practices to interpret kidney-specific results quickly and easily in line with the latest recommendations. The Pronefra app was the result. We have received very positive feedback on the app so far and hope it will help practices improve the quality and length of life of their renal patients."
Virbac is also providing further Pronefra practice support materials, include a pet health recording book for clients to aid in compliance and other educational tools for vets, nurses and clients.
Richard Malik from the Centre for Veterinary Education at the University of Sydney and Mike Lappin from Colorado State University, known for their amusing and questioning presentations, will be joined by experts including Jayne Sykes, Séverine Tasker, Donato Traversa and Francesca Mancianti to present the latest information about the diagnosis and treatment of a veritable smorgasbord of feline infectious diseases, including heartworm, leishmaniasis, toxocara, aspergillus, bartonella, coronavirus, erlichia, anaplasma, rickettsia, lungworm, mycobacteria, FeLV, FIV, haemoplasmas, cryptococcosis, GI disease and emerging feline pathogens.
Together with a mini-symposia organised by the congress sponsors – Idexx, Hill’s, Ceva, Bayer and Boehringer Ingelheim – the five-day event is worth 25 hours of feline CPD.
If you need more in-depth knowledge of feline infectious diseases, there are also three masterclasses planned.
The venue looks drop-dead gorgeous too. Set on a small wooded peninsula embraced by two harbours, Cavtat has a pretty waterfront peppered with restaurants, pebbly beaches and an interesting assortment of artsy attractions, making it one of the most desirable tourist destinations in the region. ISFM says it's a great base from which to explore Dubrovnik and the surrounding area.
The welcome party will take place at the congress hotel’s waterfront restaurant on Thursday evening.
Tickets cost £475 for ISFM members and £605 for non-members. Masterclasses are an additional £50 each.
That seems like an absolute steal to me, and I'm not even a vet. Where do I sign?
Ah, here it is: https://icatcare.org/isfm-congress
Practices which want to buy the alternative imported vaccine will need to apply to the VMD for a Special Import Certificate (SIC).
Wholesalers have agreed to stock the alternative vaccine.
Zoetis says it acknowledges the concern and frustration this causes its customers and wants to reassure the equine community that it is working hard to resume Equip Rotavirus supply as soon as possible.
For further information, contact your Zoetis account manager or ring Zoetis HQ on 0345 300 8034.
A new injectable antibiotic with nil-milk-withhold licensed to treat foul-in-the-foot in a single shot has been launched by Pfizer Animal Health.
Naxcel Cattle's active ingredient is ceftiofur in a patented sustained-release formulation. According to the company, one injection provides a full course of antibiotic therapy, giving seven days of therapeutic blood levels against the majority of inter-digital necrobacillosis ('foul-in-the-foot') pathogens.
Pfizer vet Dave Gilbert says the expectation is that Naxcel Cattle will make on-farm therapy easier and help improve treatment compliance and thereby first treatment success rates, compared to treatments which require repeat injections. "Having the full course in a single injection simplifies treatment protocols and eliminates a number of reasons for non-completion of treatment, such as forgetting a second or third dose, or not giving them because of apparent symptomatic recovery from the condition."
The site of injection for Naxcel Cattle is the subcutaneous area at the base of the ear (see Figures 1 & 2). Injection instructions are supplied in the product pack. Dave Gilbert suggests that provided cattle are adequately restrained during administration the injection technique is simple and straightforward. The dose rate is 1ml/30kg body weight and up to 30ml can safely be given into each site.
Figure 1. Subcutaneous administration of Naxcel Cattle at the posterior aspect of the ear where it attaches to the head (base of ear).Figure 2. Injection location for the subcutaneous administration of Naxcel Cattle at the posterior aspect of the ear where it attaches to the head (base of ear).
Vetoquinol UK Ltd is launching a dedicated large animal/equine sales force on the 1st July.
The company says the move reflects the change in cattle and equine veterinary practice to become specialists.
Vetoquinol's large animal brands include: Marbocyl®, Sedalin®, Equistro®, Tolfine®, Pro Rumen and Locatim®.
The new team comprises:
The new sales team will be managed jointly by Hugh Gibson and Stuart Wade.
For further information or to make an appointment please contact your local Territory Manager direct or telephone 01280 825424
MSD says the new Bravecto Care Programme involves collaborating with charitable organisations and raising awareness of their mission in order to help save and improve lives of dogs and cats around the world.
StreetVet has become the first of these partnerships for MSD Animal Health in the UK, which will be supplying the charity with Bravecto and Nobivac vaccines.
Amanda Melvin, Marketing Manager for MSD Animal Health Companion Animal said: "The bond between people and their dogs can be a profound one so supporting StreetVet is a perfect collaboration for us through our Bravecto Care Programme . Every vet and vet nurse will understand the value of this vital human animal bond and our team at MSD Animal Health is excited to be providing product and looking forward to volunteering on the streets with the StreetVet team."
StreetVet co-founder Jade Statt said: "Life on the streets makes it difficult for these owners to access the care they need for their dogs, so to ensure the health and vitality of these pets we need to go to them. Having the support of MSD Animal Health helps make that care work easier and allows us to access even more homeless people as the problem grows."
For more information, visit: www.streetvet.co.uk.
It is not the first time Roundhouse Referrals has innovated in this area. Last year, it launched the first 'Fixed Price TPLO' - a guarantee that pet owners will have no additional costs, should complications arise and further treatment be required following surgery.
Ross Allan, RCVS Advanced Practitioner in Small Animal Surgery and Surgical Lead at Roundhouse Referrals, said: "We loved the idea of providing price certainty for referral clients, allowing those with no or lower levels of insurance to access our services and plan their finances. We also realised that in putting 'Fixed Price Fix' first and foremost we are also immediately highlight the possibility of complications and we felt the very best way to provide context for owners and referring vets would be to be open about our outcomes."
Following on from this Roundhouse Referrals has published the first of what it says will be a series of reports on TPLO+ clinical outcomes and customer satisfaction.
Ross said: "I think we're the first in Scotland to publish this kind of information outside scientific journals in a way that is easily accessible for pet owners, maybe in the whole of the UK."
The clinical outcome data was collected using a previously published questionnaire which enabled clients to give feedback on their pet’s recovery and status following their TPLO+ surgery.
According to Roundhouse, the results show that over 97% of dog owners rated their pets’ outcome as either excellent (85.29%) or good (11.76%) based on the first 70 TPLO+ surgeries performed. A figure which Ross says compares favourably with studies that have been previously published.
Additionally, 94.1% of pet owners agreed that if faced with having to make a similar decision again, they would choose to have the TPLO+ surgery done at Roundhouse Referrals, compared to 84.6% of owners in the previous study.
The results from the Customer Satisfaction Questionnaire showed that 100% of Roundhouse Referrals’ clients felt supported throughout the referral process, 96.97% of clients felt that the TPLO+ surgery was adequately explained and 100% would recommend Roundhouse Referrals to a friend or colleague.
Ross said: "Pet owners whose dogs’ had been through TPLO+ surgery and rehabilitation completed this questionnaire, enabling us to start measuring the outcome of the surgery, our aim being to ensure the surgery is optimal for the pet, and that owners feel supported throughout the entire surgical journey.
"We are delighted with these results, and will continue to monitor our outcomes and commit to publish our TPLO+ clinical outcome and customer satisfaction questionnaire results in the months and years ahead".
The company says the new addition leverages a combination of image recognition technology, algorithms, and cloud-based deep learning AI to enable accurate, in-clinic sediment analysis of fresh urine, delivering results within minutes.
The system evaluates red and white blood cells, squamous and other epithelial cells (e.g. urothelial and renal tubular epithelial cells), hyaline and non-hyaline casts, struvite and calcium oxalate dihydrate crystals, and cocci and rod bacteria.
Zoetis says its performance is comparable to that of a clinical pathologist.
Richard Goldstein, DVM, DACVIM, DECVIM-CA, Vice President and Chief Medical Officer, Global Diagnostics Medical Affairs at Zoetis said: “Urinalysis is an essential diagnostic test for veterinary surgeons, and often a good indicator of potential wider issues.
"Having the ability to get these results faster will improve the speed and level of care teams can provide their patients, facilitating efficient medical decision-making and helping to ensure smooth workflows.
Focusing on the approach, diagnosis and treatment of regurgitation in dogs and cats, the webinar looks at how to differentiate regurgitation from vomiting and the way some diseases can cause inflammation, obstruction or dysmotility of the oesophagus, which can often result in regurgitation.
Aarti Kathrani graduated from the Royal Veterinary College (RVC) and is now a Senior Lecturer in Small Animal Internal Medicine, where she is involved with the clinical internal medicine service. She also helps provide nutritional input to clinical cases seen at the Queen Mother Hospital for Animals, where her research centres on canine and feline gastroenterology and nutrition.
Aarti said: “The webinar is designed to help general practitioners differentiate between regurgitation and vomiting, as well as provide a comprehensive review of the different causes of regurgitation and the diagnostic approach to this. Treatment is also discussed for this condition. We hope the webinar provides a useful guide to help diagnose and manage these cases in general practice.”
The regurgitation lecture is freely available and can be accessed via the Webinar Library here: https://www.bsavalibrary.com/content/webinar-library.
The lecture complements the BSAVA Manual of Canine and Feline Gastroenterology, which was published in 2019 to give readers a greater insight into the GI conditions they are treating. The Manual is divided into four main sections, focusing on; Diagnostic procedures and techniques; Diagnostic approaches to problems; Patient Management; Diseases of specific systems/organs.
The Manual costs £60.00 for BSAVA members; £90.00 for non-members and can be purchased from the BSAVA website here: https://www.bsava.com/Shop/Veterinary-books#!prod/f1a8220f-3ff7-e911-80e7-005056be4acd/curr/GBP
Trilotab is licensed for the treatment of pituitary-dependent hypercortisolism (PDH) caused by an adrenocorticotrophic hormone (ACTH)-secreting pituitary adenoma, which accounts for 85% of spontaneous cases of Cushing’s, and for the treatment of adreno-dependent hyperadrenocorticism (ADH) caused by a cortisol-secreting adrenocortical tumour (ACT), which accounts for the remaining 15% of spontaneous cases1.
The new tablet is divisible into halves and quarters to facilitate dose adjustment and make administration easier.
Divided tablets remain stable outside of the blister packaging until the next dose is due, thereby avoiding wastage.
Trilotab tablets are chewable and chicken-flavoured to help improve treatment compliance.
They contain hydrolysed chicken flavouring so they can be prescribed for pets allergic to chicken.
Trilotab is administered once daily with food with a starting dose of 2mg trilostane/kg bodyweight.
The new tabs are available in three presentations: 10mg, 30mg, and 60mg presentations, which Virbac says should help practices reduce their dispensary stockholding.
Andrew Connolly, Marketing Director – UK & Ireland at Virbac, said: ‘The complex nature of Cushing’s syndrome in dogs can make it a challenging condition to manage for both the clinician and the pet owner.
"With the requirement for lifelong treatment, it is our hope that Trilotab’s easy administration and simplified dosing protocols will genuinely help to improve the lives of dogs affected by the disease, whilst making the clinician and pet owner’s lives just a little bit easier too!"
Reference
The event offers over 30 hours of CPD, covering topics which have been chosen to represent the current areas of practical interest for veterinary professionals, from ethics and behaviour to critical care and pain assessment.
The online event was developed after the coronavirus pandemic forced the cancellation of ISFM's annual European Congress.
There will be two separate lecture streams, one for vets and one for veterinary nurses and technicians, alongside several sponsor-led symposiums, live question and answer sessions, and a virtual exhibition hall.
In recognition of attendance, CPD certificates will be available to download from the platform.
In the vet stream, topics include the assessment and management of pain in cats, ethics, analgesia and anaesthesia, point of care ultrasound, nutrition and critical care. International expert speakers will give the latest research in their respective fields, whilst ensuring that their talks and lectures remain practical, with ‘take-home’ information applicable in clinics.
The ISFM is at pains to recognise the generosity of Bayer, Boehringer Ingelheim, Ceva, Hill’s, Purina, Idexx and Royal Canin, which has made it possible to provide the congress free of charge.
Registration opens today. For more information and to register, visit: https://icatcare.org/isfm-international-congress/
As Ceva points out, the change gives veterinary surgeons an opportunity to get more involved in parasite control plans and help farmers develop a sustainable parasite control strategy on their farm.
Eprecis injectable contains eprinomectin, the only molecule with zero-milk withdrawal currently available for cattle on the U.K. market.
Ceva highlights that because Eprecis is an injection, there is no risk of product transfer between in-contact animals caused by licking1,2,3 a natural behaviour of cattle, potentially resulting in sub-therapeutic levels of product being absorbed. There is also no risk of reduction in efficacy if dirt or manure is present on the back of the animal4.
The company says injectable formulation results in less active ingredient per animal treated compared to eprinomectin pour-ons; for example using Eprecis injection, a 500kg animal receives 100mg eprinomectin, while a pour-on delivers 250mg per application.
To support the new POM-V classification, Ceva has launched a vet support pack to help veterinary professionals when talking to their farming clients about Eprecis, worming strategies and their parasite control plans. The pack contains a farmer targeted brochure, farmer Q&A and a practical guide with suggestions of when Eprecis can be used. It also includes an infograph for social media posts, a technical booklet and a vet Q&A to help answer the most common questions they may be asked. A series of social media posts are available for vet practices encouraging their clients to discuss worming with their vet.
Kythé Mackenzie BVSc MRCVS, ruminant veterinary adviser at Ceva Animal Health, said: “Ruminants can be parasitised by a range of nematodes, trematodes and external parasites, all of which can have an impact on health and production. A recent publication considered that helminth infections (GIN, lungworm and liver fluke) cost the UK dairy industry close to £145M per year5. Interestingly, the majority of these costs were attributed to lost production (£131M) rather than treatment costs (£14M).
“There is now documented resistance to eprinomectin in small ruminants6 (Haemonchus contortus in goats) and whilst not yet documented in cattle, action needs to be taken to try and delay/minimise this emergence. This requires the use of more sustainable parasite control plans to assist in managing refugia and allowing animals adequate exposure to the parasites to develop natural immunity. Parasite control plans should maximise health, welfare and production whilst minimising the unnecessary use of anthelmintics.”
In the short-term, orders of Eprecis injectable from veterinary wholesalers will be fulfilled by the current POM-VPS product that is in the supply chain before switching to the new packaging later in the season.
For further information contact your local Ceva Animal Health territory manager or email cevauk@ceva.com.
References
The training facility is over 800m2 and houses 18 working stations, three lecture rooms, the latest training technology, a leisure area and library with outdoor space and parking.
Heber Alves, CEO of the Improve International Group said: “It has been a goal of ours for a long time to open a new, top-of-the-range training facility for veterinary professionals in Germany.
"We are delighted to see this dream come true and we are very excited to now have the opportunity to work more closely with vets and veterinary technicians and help them grow their skillsets.”
www.improveinternational.com.
In response to the question ‘How important is sustainability to you personally?’, 57% of respondents said it was very important making it the most popular choice.
However, in answer to the question: ‘Is your practice team actively working to improve sustainability?’, 20% of respondents said ‘Always/wherever possible’ and 42% said ‘Most of the time’, leaving 38% not actively working to improve sustainability.
IVC says the conclusion to be drawn is that sustainability is a personal priority, but this isn’t always translating to practice and more can be done.
To help with this, the company will shortly Positive Hoofprint, an Equine and Farm specific toolkit to help practices become more sustainable, with resources, checklists and practical advice for prioritising environmentally friendly initiatives.
Mark Tabachnik, UK Head of Equine for IVC Evidensia, said: “It’s clear from our survey that sustainability is still being treated as a secondary concern in practice, and this is something that IVC Evidensia is actively seeking to change.
“With our Positive Hoofprint about to be launched, there has never been a better time to prioritise our sustainability goals and to embed them in our own practices.
“This will give colleagues the tools they need to care for the planet, so we can fundamentally change equine veterinary to be more environmentally conscious for the future.”
Ceva Animal Health has launched Feliway Friends, a new pheromone to help reduce tensions and conflicts in households with more than one cat.
The company highlights a 2014 survey which found that 44% of cat owning households have more than one cat, with nearly a third of those questioned stating that they had experienced fighting and aggression between pets in the household1.
Feliway Friends is a synthetic copy of the cat appeasing pheromone (CAP) naturally produced by nursing queens to support their kittens after birth. The company says this pheromone helps cats feel safe and secure, and maintains a harmonious bond between them.
Ceva says Feliway Friends is clinically proven to significantly decrease the intensity and frequency of signs of tension in households with more than one cat. According to another study, 84% of cat owners believed there was a significant improvement in how their cats got on after using the product2.
Feliway Friends and Feliway Classic can be used at the same time if the owner is experiencing conflicts alongside other stress-related behaviour problems such as urine marking, scratch marking and general anxiety.
Available as a 30-day diffuser and refill, Feliway Friends lasts for up to 30 days and covers an area of up to 70m2.
Claire Russell, Feliway product manager at Ceva Animal Health, said: "Inter-cat aggression is a major problem in multi-cat households, with many cats experiencing stress in the home due to sharing resources. Feliway Friends is a great support to encourage harmony in multi-cat homes. By introducing the cat appeasing pheromone and educating owners on resource management and how to create a cat friendly home, we can significantly improve feline relationships in our UK multi-cat homes.’’
Ceva Animal Health has launched a range of marketing materials to support the launch of the new product, including an eight-page pet owner leaflet and poster. Practices can also request an online toolkit which includes: images, website content, social media assets and articles to help educate clients facing aggression between household cats.
For information on FELIWAY visit www.feliway.com/uk.
Surrey-based Sarah Taylor and Zoe Daley launched the website earlier this year with a range which includes the Medicat wrap to make it easier to medicate and examine cats, and the Slumberpet Recovery Coat for dogs and for cats, for maintaining temperature during anaesthetics.
In addition, they've got a range of funky scrub caps, plus ID tags for your scissors and stethoscopes, fob watches, scrub hats and pens.
Norbrook Laboratories has launched Closamectin, a parasiticide which the company says will revolutionise cattle farming and parasite control in meat producing animals.
Closamectin Pour-on is a solution which can quite literally be poured onto the back of animals. It simultaneously treats fluke, worms and external parasites. The new product is the culmination of a six year research project costing £3.5 million and involving 80 scientists at the company's headquarters in Newry Co Down.
Norbrook says it will bring immense benefits for farmers whose cattle are often ravaged by parasitic attack. Fluke in particular can have devastating effects both on beef and dairy herds, seriously weakening, and in some cases killing the animals by destroying their livers. At the very least it collectively costs farmers around £17 million per annum by reducing the weight of beef cattle and the milk yields of dairy cows.
Fluke used to be confined to the western parts of Britain, together with Scotland and Ireland, but global warming has seen other parts of the UK experiencing the same mild and wet conditions on which the parasite thrives. Consequently it is on the rise.
Currently fluke is treated by injection or oral drench - both time-consuming and difficult processes for the farmers which can also be stressful for the animals. In contrast pour-on solutions can be applied swiftly and easily with no detrimental impact on cattle.
Norbrook has been awarded licenses for Closamectin Pour-on in both the UK and Ireland. This is a very significant market: the countries have a combined cattle population of 17 million. There are also plans to roll out the product in other countries.
Developing a pour-on to deal with these parasites has baffled scientists for 20 years. Alistair Couper, Norbrook's Chief Vet said: "This is the Holy Grail of farm animal veterinary medicine. It was a highly complex challenge for our research team. They had to develop a product which would treat different conditions simultaneously and have a molecular structure which could be absorbed straight through the skin. This is a ground breaking achievement and a brilliant piece of science"
Lord Ballyedmond, Chairman of Norbrook Laboratories said: "This is a very important milestone for Norbrook and for livestock and farmers worldwide. We have invested heavily in research and development and the results are there for all to see. We are delighted to have beaten other multinationals. We have now developed the world's most effective remedy for parasite control in cattle that our entering the food chain. I am pleased to state that our business has grown this year indigenously at 12% despite the recession, beating our competitors. This tremendous breakthrough is a great testimony to the brilliance of our scientists in Newry and also to our policy of investing in research. "
Vetigel is a plant based gel which was first introduced to the UK for orthodontic surgeries last year.
It is supplied in a pre-filled syringe and applied directly to the site of bleeding where it creates an initial mechanical seal and then supports the formation of the platelet plug below.
VetPlus says it can be used in many situations where bleeding is an issue and the gel can be applied directly to the site of bleeding, including liver biopsies, mass removals, amputations and enucleations.
Jackie Marshall, VetPlus Technical Advisor, said: “This innovative product is already transforming the way vets perform both dental and surgical procedures, and we have had really positive feedback from those practices where it is being used already.
"Vetigel isn’t intended to replace a surgeon’s technique, but it is designed to stop bleeding where pressure or other methods are ineffective or impractical.
"Because it is a gel, it can conform to a wide range of wound shapes, making it a rapid, effective way of controlling bleeding.
“We believe this product will make a lasting impact on veterinary care, transforming the way surgeries are carried out and assisting haemostasis in animal patients.”
Zak Leavold, a vet based at Calster Vets in Great Yarmouth used Vetigel in an emergency situation, out of hours, on a dog with a bleed due to a kidney laceration.
He said: ‘I genuinely believe the product saved the dog’s life that night.
"I will certainly be keeping Vetigel on hand for any future soft surgeries – just in case!’
Links